After a year of remarkable change in pancreatic cancer care, John Chabot, MD, takes stock of what has shifted, explores what these advances mean for patients, and where the field is headed next.
After decades of progress measured in inches, pancreatic cancer may finally be entering a moment where the questions are no longer only about what treatment can do, but how far that treatment might take us.
Pancreatic surgeon Dr. Beth Schrope starts her mornings without an alarm, enters the OR right foot first, and never overlooks the small things that can make a patient’s day a little easier.
As the FDA approved a new targeted therapy for metastatic pancreatic cancer, an early-stage Columbia trial offers another encouraging signal that one of cancer’s most stubborn diseases may be entering a new era of treatment.
An interview with John A. Chabot, MD, Chief of the Division of GI/Endocrine Surgery and Executive Director of the Pancreas Center, about the latest in pancreatic care.
We are thrilled to announce the winners of the 2024 Ruth Leff Seigel Awards for pancreatic cancer research, Sita Kugel, PhD and Kazuki N. Sugahara, MD, PhD.
